Global Veterinary/Animal Vaccines Market

1 INTRODUCTION OF GLOBAL VETERINARY/ANIMAL VACCINESMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL VETERINARY/ANIMAL VACCINESMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, BY TECHNOLOGY
5.1 Live Attenuated Vaccines
5.2 Inactivated Vaccines
5.3 Toxoid Vaccines
5.4 Recombinant Vaccines
5.5 Other Vaccines

6 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, BY TYPE
6.1 Porcine Vaccines
6.2 Poultry Vaccines
6.3 Livestock Vaccines
6.3.1 Bovine
6.3.2 Small Ruminant
6.4 Companion animals vaccines
6.4.1 Canine
6.4.2 Feline
6.5 Aquaculture vaccines
6.6 Others

7 GLOBAL VETERINARY/ANIMAL VACCINES MARKET, BY DISEASE
7.1 Porcine
7.2 Poultry
7.3 Livestock
7.3.1 Bovine
7.3.2 Small Ruminant
7.4 Companion animals
7.4.1 Canine
7.4.2 Feline
7.5 Aquaculture
7.6 Others

8 GLOBAL VETERINARY/ANIMAL VACCINESMARKET, BY GEOGRAPHY
8.1 Overview
8.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

9 GLOBAL VETERINARY/ANIMAL VACCINESMARKETCOMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES
10.1 Zoetis
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments

10.2 Merck Animal Health
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments

10.3 BoehringerIngelheim
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments

10.4 Elanco
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments

10.5 Ceva
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments

10.6 Virbac
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments

10.7 Vetoquinol
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments

10.8 Phibro Animal Health
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments

10.9 Hester
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Development

10.10 Hipra
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Development

10.11 IdtBiologika
10.11.1 Overview
10.11.2 Financial Performance
10.11.3 Product Outlook
10.11.4 Key Development

10.12 Biogenesis Bago
10.12.1 Overview
10.12.2 Financial Performance
10.12.3 Product Outlook
10.12.4 Key Development

10.13 Tianjin Ringpu
10.13.1 Overview
10.13.2 Financial Performance
10.13.3 Product Outlook
10.13.4 Key Development

10.14 China Animal Husbandry
10.14.1 Overview
10.14.2 Financial Performance
10.14.3 Product Outlook
10.14.4 Key Development

10.15 Jinyu Bio-Technology
10.15.1 Overview
10.15.2 Financial Performance
10.15.3 Product Outlook
10.15.4 Key Development

11 Appendix
11.1 Related Reports